Contribute Try STAT+ Today

An inactivated form of the poliovirus used to treat recurrent brain tumors is showing what researchers called encouraging long-term survival in a Phase 1 clinical trial published Tuesday.

The authors reported that 21 percent of patients were still alive three years after the recurrence of glioblastoma, an aggressive and quickly lethal form of brain cancer that is stubbornly resistant to treatment — even the new crop of immunotherapies have proven to be ineffective. Against that bleak backdrop, the early results suggest the experimental poliovirus therapy, invented at Duke Cancer Institute, has some promise.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.